Christine D Czoli1, Geoffrey T Fong1,2,3, Maciej L Goniewicz4, David Hammond1. 1. School of Public Health and Health Systems, University of Waterloo, Waterloo, ON, Canada. 2. Department of Psychology, University of Waterloo, Waterloo, ON, Canada. 3. Ontario Institute for Cancer Research, Toronto, ON, Canada. 4. Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Abstract
INTRODUCTION: "Dual use" refers to the concurrent use of tobacco cigarettes (smoking) and electronic cigarettes (e-cigarettes; vaping). Although dual use is common among e-cigarette users, there is little evidence regarding biomarkers of exposure among dual users and how these change under different conditions of product use. METHODS: A nonblinded within-subjects crossover experiment was conducted with adult daily dual users (n = 48) in Ontario, Canada. Participants completed three consecutive 7-day periods in which the use of tobacco cigarettes and e-cigarettes was experimentally manipulated, resulting in four study conditions: Dual use, Tobacco cigarette use, E-cigarette use, and No product use. Repeated measures models were used to examine changes in product use and biomarkers of exposure. RESULTS: Compared to dual use, cotinine remained stable when participants exclusively smoked (p = .524), but significantly decreased when they exclusively vaped (p = .027), despite significant increases in e-cigarette consumption (p = .001). Levels of biomarkers of exposure to toxicants, including carbon monoxide (CO), 1-hydroxypyrene (1-HOP), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), were significantly lower when participants exclusively vaped than when they engaged in dual use (CO = -41%, p < .001; 1-HOP = -31%, p = .025; NNAL = -30%, p = .017). Similar findings were observed among participants abstaining from both products as compared to dual use (CO: -26%, p < .001; 1-HOP = -14% [ns]; NNAL = -35%, p = .016). In contrast, levels of biomarkers of exposure increased when participants exclusively smoked as compared to dual use (CO = +21%, p = .029; 1-HOP = +23%, p = .048; NNAL = +8% [ns]). CONCLUSIONS: Although dual use may reduce exposure to tobacco smoke constituents to some extent, abstaining from smoking is the most effective way to reduce such exposure. IMPLICATIONS: Public health authorities should clearly communicate the relative risk of e-cigarettes and tobacco cigarettes to the general public, focusing on two salient points: (1) e-cigarettes are not harmless, but they are less harmful than tobacco cigarettes; and (2) using e-cigarettes while smoking may not necessarily reduce health risks; therefore, consumers should stop smoking completely to maximize potential health benefits.
INTRODUCTION: "Dual use" refers to the concurrent use of tobacco cigarettes (smoking) and electronic cigarettes (e-cigarettes; vaping). Although dual use is common among e-cigarette users, there is little evidence regarding biomarkers of exposure among dual users and how these change under different conditions of product use. METHODS: A nonblinded within-subjects crossover experiment was conducted with adult daily dual users (n = 48) in Ontario, Canada. Participants completed three consecutive 7-day periods in which the use of tobacco cigarettes and e-cigarettes was experimentally manipulated, resulting in four study conditions: Dual use, Tobacco cigarette use, E-cigarette use, and No product use. Repeated measures models were used to examine changes in product use and biomarkers of exposure. RESULTS: Compared to dual use, cotinine remained stable when participants exclusively smoked (p = .524), but significantly decreased when they exclusively vaped (p = .027), despite significant increases in e-cigarette consumption (p = .001). Levels of biomarkers of exposure to toxicants, including carbon monoxide (CO), 1-hydroxypyrene (1-HOP), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), were significantly lower when participants exclusively vaped than when they engaged in dual use (CO = -41%, p < .001; 1-HOP = -31%, p = .025; NNAL = -30%, p = .017). Similar findings were observed among participants abstaining from both products as compared to dual use (CO: -26%, p < .001; 1-HOP = -14% [ns]; NNAL = -35%, p = .016). In contrast, levels of biomarkers of exposure increased when participants exclusively smoked as compared to dual use (CO = +21%, p = .029; 1-HOP = +23%, p = .048; NNAL = +8% [ns]). CONCLUSIONS: Although dual use may reduce exposure to tobacco smoke constituents to some extent, abstaining from smoking is the most effective way to reduce such exposure. IMPLICATIONS: Public health authorities should clearly communicate the relative risk of e-cigarettes and tobacco cigarettes to the general public, focusing on two salient points: (1) e-cigarettes are not harmless, but they are less harmful than tobacco cigarettes; and (2) using e-cigarettes while smoking may not necessarily reduce health risks; therefore, consumers should stop smoking completely to maximize potential health benefits.
Authors: Blair N Coleman; Brian Rostron; Sarah E Johnson; Bridget K Ambrose; Jennifer Pearson; Cassandra A Stanton; Baoguang Wang; Cristine Delnevo; Maansi Bansal-Travers; Heather L Kimmel; Maciej L Goniewicz; Raymond Niaura; David Abrams; Kevin P Conway; Nicolette Borek; Wilson M Compton; Andrew Hyland Journal: Tob Control Date: 2017-06-17 Impact factor: 7.552
Authors: Deesha Patel; Kevin C Davis; Shanna Cox; Brian Bradfield; Brian A King; Paul Shafer; Ralph Caraballo; Rebecca Bunnell Journal: Prev Med Date: 2016-09-07 Impact factor: 4.018
Authors: Roberta Pacifici; Simona Pichini; Silvia Graziano; Manuela Pellegrini; Giuseppina Massaro; Fabio Beatrice Journal: Int J Environ Res Public Health Date: 2015-07-08 Impact factor: 3.390
Authors: Konstantinos E Farsalinos; Giorgio Romagna; Dimitris Tsiapras; Stamatis Kyrzopoulos; Alketa Spyrou; Vassilis Voudris Journal: Int J Environ Res Public Health Date: 2013-12-17 Impact factor: 3.390
Authors: Jennifer L Pearson; Hoda Elmasry; Babita Das; Sabrina L Smiley; Leslie F Rubin; Teresa DeAtley; Emily Harvey; Yitong Zhou; Raymond Niaura; David B Abrams Journal: JMIR Res Protoc Date: 2017-05-29
Authors: Shu-Hong Zhu; Jessica Y Sun; Erika Bonnevie; Sharon E Cummins; Anthony Gamst; Lu Yin; Madeleine Lee Journal: Tob Control Date: 2014-07 Impact factor: 7.552
Authors: Jennifer L Pearson; Yitong Zhou; Sabrina L Smiley; Leslie F Rubin; Emily Harvey; Brandon Koch; Raymond Niaura; David B Abrams Journal: Nicotine Tob Res Date: 2021-02-16 Impact factor: 4.244
Authors: Danielle M Smith; Carol Christensen; Dana van Bemmel; Nicolette Borek; Bridget Ambrose; Gladys Erives; Raymond Niaura; Kathryn C Edwards; Cassandra A Stanton; Benjamin C Blount; Lanqing Wang; Jun Feng; Jeffery M Jarrett; Cynthia D Ward; Dorothy Hatsukami; Stephen S Hecht; Heather L Kimmel; Mark Travers; Andrew Hyland; Maciej L Goniewicz Journal: Nicotine Tob Res Date: 2021-05-04 Impact factor: 4.244
Authors: Dana Rubenstein; Alexander W Sokolovsky; Elizabeth R Aston; Nicole L Nollen; Christopher H Schmid; Myra Rice; Kim Pulvers; Jasjit S Ahluwalia Journal: Addict Behav Date: 2021-07-01 Impact factor: 3.913
Authors: Eleanor L S Leavens; Nicole L Nollen; Jasjit S Ahluwalia; Matthew S Mayo; Myra Rice; Emma I Brett; Kim Pulvers Journal: Addiction Date: 2021-07-05 Impact factor: 6.526
Authors: Shannon Gravely; Geoffrey T Fong; Edward Sutanto; Ruth Loewen; Janine Ouimet; Steve S Xu; Anne C K Quah; Mary E Thompson; Christian Boudreau; Grace Li; Maciej L Goniewicz; Itsuro Yoshimi; Yumiko Mochizuki; Tara Elton-Marshall; James F Thrasher; Takahiro Tabuchi Journal: Int J Environ Res Public Health Date: 2020-04-01 Impact factor: 3.390
Authors: Isaac Armendáriz-Castillo; Santiago Guerrero; Antonella Vera-Guapi; Tiffany Cevallos-Vilatuña; Jennyfer M García-Cárdenas; Patricia Guevara-Ramírez; Andrés López-Cortés; Andy Pérez-Villa; Verónica Yumiceba; Ana K Zambrano; Paola E Leone; César Paz-Y-Miño Journal: Biomed Res Int Date: 2019-12-19 Impact factor: 3.411